Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Demonstration device
Demonstration device for healthcare professionals to show patients how to use the Ellipta device correctly. Visit resources page to order.
Anoro Ellipta dosing: The recommended (and maximum) dose is one inhalation of Anoro Ellipta (UMEC/VI 55/22 micrograms) once daily.
The dose should be administered at the same time of the day each day to maintain bronchodilation.
Please refer to the SmPC for further information prior to prescribing.
Click on the video below to see how to use the Ellipta inhaler
An easy-to-use COPD inhaler can help your patient receive the right dose1-3
Poor inhaler technique could be a reason why a patient's COPD symptoms are poorly controlled.3
In a single-visit, open-label, crossover study, significantly fewer COPD patients made a critical error* with the Ellipta inhaler compared with other commonly used COPD inhalers (Accuhaler, MDI, Turbohaler, HandiHaler, Breezhaler) after reading the patient information leaflet (PIL); (p<0.001 for all comparisons).**1
*A critical error is defined as those likely to result in the inhalation of significantly reduced, minimal or no medication.1
% of patients making ≥ one critical error after reading the PIL with Ellipta vs. HandiHaler**1
3.4x fewer patients made a critical error* with Ellipta vs. HandiHaler
(Ellipta 14% (17/118); HandiHaler 48% (57/118); p<0.001)
**This was a multi-centre, single visit, randomised, open-label, cross-over study to investigate errors in the use of different inhalers in patients with COPD. Patients were randomised to receive either Ellipta or another commonly used COPD inhaler (Accuhaler, MDI, Turbohaler, HandiHaler, Breezhaler). Patients were naive to the inhalers under investigation in their study arm.1
Support your patients starting on Anoro Ellipta maintenance therapy
References
- van der Palen J et al. NPJ Prim Care Respir Med 2016;26:16079.
- Svedsater H et al. BMC Pulm Med 2013;13:72–86.
- Riley JH et al. Int J Chron Obstruct Pulm Dis 2016;11:1873–1880.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie .
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Anoro is a registered trademark of the GlaxoSmithKline group of companies.
PM-IE-UCV-WCNT-210016 June 2023
